{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:34:40Z","timestamp":1790112880951,"version":"4.0.1"},"reference-count":39,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,12,26]],"date-time":"2016-12-26T00:00:00Z","timestamp":1482710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ContraVir Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      This prospective, parallel\u2010group, randomized, double\u2010blind, multicenter study compared the efficacy and safety of FV\u2010100 with valacyclovir for reducing pain associated with acute herpes zoster (HZ). Patients, \u226550 years of age, diagnosed with HZ within 72 h of lesion appearance who had HZ\u2010associated pain, were randomized 1:1:1 to a 7\u2010day course of either FV\u2010100 200\u2009mg QD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009117), FV\u2010100 400\u2009mg QD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009116), or valacyclovir 1000\u2009mg TID (\n                      <jats:italic>n<\/jats:italic>\n                      =117). Efficacy was evaluated on the basis of the burden of illness (BOI; Zoster Brief Pain Inventory scores); incidence and duration of clinically significant pain (CSP); pain scores; incidence and severity of post\u2010herpetic neuralgia (PHN); and times to full lesion crusting and to lesion healing. Safety was evaluated on the basis of adverse event (AE)\/SAE profiles, changes in laboratory and vital signs values, and results of electrocardiograms. The burden of illness scores for pain through 30 days were 114.5, 110.3, and 118.0 for FV\u2010100 200\u2009mg, FV\u2010100 400\u2009mg, and valacyclovir 3000\u2009mg, respectively. The incidences of PHN at 90 days for FV\u2010100 200\u2009mg, FV\u2010100 400\u2009mg, and valacyclovir 3000\u2009mg were 17.8%, 12.4%, and 20.2%, respectively. Adverse event and SAE profiles of the two FV\u2010100 and the valacyclovir groups were similar and no untoward signals or trends were evident. These results demonstrate a potential for FV\u2010100 as an antiviral for the treatment of shingles that could both reduce the pain burden of the acute episode and reduce the incidence of PHN compared with available treatments.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jmv.24750","type":"journal-article","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T07:37:30Z","timestamp":1481528250000},"page":"1255-1264","source":"Crossref","is-referenced-by-count":21,"title":["FV\u2010100 versus valacyclovir for the prevention of post\u2010herpetic neuralgia and the treatment of acute herpes zoster\u2010associated pain: A randomized\u2010controlled trial"],"prefix":"10.1002","volume":"89","author":[{"given":"Stephen K.","family":"Tyring","sequence":"first","affiliation":[{"name":"University of Texas Health Sciences Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Clinical Studies Webster Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Gordon T.","family":"Hill","sequence":"additional","affiliation":[{"name":"Oakwell Clinical Research LLC San Antonio Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel C.","family":"Silverfield","sequence":"additional","affiliation":[{"name":"Bay Care Medical Group, Inc. Health Point Medical Group, Inc. Burnette and Silverfield MDS Tampa Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Yen","family":"Moore","sequence":"additional","affiliation":[{"name":"Arlington Center for Dermatology Arlington Research Center Arlington Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Matkovits","sequence":"additional","affiliation":[{"name":"ContraVir Pharmaceuticals, Inc. Edison New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Sullivan\u2010Bolyai","sequence":"additional","affiliation":[{"name":"ContraVir Pharmaceuticals, Inc. Edison New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,12,26]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Center for Disease Control and Prevention. What you need to know about the shingles vaccine. Available at:http:\/\/www.cdc.gov\/vaccines\/hcp\/patient\u2010ed\/adults\/downloads\/fs\u2010shingles.pdfUpdated August2014."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp013211"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.10.002"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.851"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-37"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1090-3801(99)90015-0"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000123261.00004.29"},{"key":"e_1_2_6_9_1","first-page":"861","article-title":"Post\u2010herpetic neuralgia","volume":"5","author":"Tontodonati M","year":"2012","journal-title":"Int J Gen Med"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S57242"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000307"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1086\/421942"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"e_1_2_6_14_1","unstructured":"National Health Interview Survey (NHIS). Estimated proportion of adults aged >19 years who received selected vaccinations by age group high\u2010risk status and race\/ethnicity. United States;2009.http:\/\/www.cdc.gov\/vaccines\/imz\u2010managers\/coverage\/nhis\/2009\u2010nhis.htmlAccessed March 29 2016."},{"key":"e_1_2_6_15_1","first-page":"119","article-title":"Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 Sao Paulo epidemic","volume":"11","author":"Pannuti CS","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis638"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu918"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1546"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.02.020"},{"key":"e_1_2_6_20_1","unstructured":"ZOVIRAX\u00ae (acyclovir) capsules tablets suspension [package insert] Research Triangle Park NC. GlaxoSmithKline;2005."},{"key":"e_1_2_6_21_1","unstructured":"FAMVIR\u00ae (famciclovir) tablets [package insert] Eastt Hanover NJ. Novartis Pharmaceuticals Corp.;2013."},{"key":"e_1_2_6_22_1","unstructured":"VALTREX\u00ae (valacyclovir hydrochloride) caplets [package insert] Research Triangle Park NC. GlaxoSmithKline;2008."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200320080-00002"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm376"},{"key":"e_1_2_6_25_1","unstructured":"RohanP.2005. FDA Clinical Briefing Document for Merck & Co. Inc. Zoster Vaccine Live (Oka\/Merck) Zostavax\u00ae."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2004.06.001"},{"key":"e_1_2_6_27_1","unstructured":"World Medical Association Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects;2016. Available at:http:\/\/www.wma.net\/en\/30publications\/10policies\/b3"},{"key":"e_1_2_6_28_1","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards For Expedited Reporting E2A.1994.http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E2A\/Step4\/E2A_Guideline.pdf"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(95)00066-6"},{"key":"e_1_2_6_30_1","first-page":"129","article-title":"Pain assessment: Global use of the Brief Pain Inventory","volume":"23","author":"Cleeland CS","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002508-200006001-00016"},{"key":"e_1_2_6_32_1","first-page":"CD006866","article-title":"Antiviral treatment for preventing postherpetic neuralgia","volume":"2","author":"Chen N","year":"2014","journal-title":"Cochrane Database System Rev"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2015.03.022"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1086\/522159"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200724010-00001"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2009.02089.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2005.01.359"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-92"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7264.794"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2009.09.008"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.24750","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.24750","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.24750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T16:00:58Z","timestamp":1694275258000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.24750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,26]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/jmv.24750"],"URL":"https:\/\/doi.org\/10.1002\/jmv.24750","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,26]]}}}